ð· Citalopram is an SSRI that increases serotonin levels to treat depression, and effects may take 4â6 weeks to fully improve symptoms.
ð· St. Johnâs Wort also increases serotonergic activity and can interact with SSRIs, causing dangerously high serotonin levels.
ð· Combining these increases the risk for serotonin syndrome, a potentially life-threatening condition.
ð· The nurse should recognize this as a priority medication-safety issue and instruct the client to stop the herb and notify the provider immediately.
ð· Early signs include agitation, confusion, sweating, tachycardia, diarrhea, tremor, and hyperreflexia, which require urgent evaluation if present.
anticholinergic toxicity
ð·Anticholinergic toxicity is linked to medications with strong anticholinergic properties (e.g., TCAs, antihistamines), not SSRIs like citalopram.
ð·The key risk cue here is a serotonergic herb, not anticholinergic medication exposure.
severe neutropenia
ð·Severe neutropenia is most associated with certain antipsychotics (e.g., clozapine) and some chemotherapy agents, not citalopram or famotidine.
ð· The clientâs presentation and medication list do not support a high neutropenia risk.
metabolic syndrome
ð·Metabolic syndrome is commonly related to second-generation antipsychotics, long-term weight gain, and insulin resistance.
ð·While family history is important, it does not represent the immediate medication-related risk shown in this scenario.
hyperkalemia
ð·Hyperkalemia is typically linked to kidney disease or medications like ACE inhibitors, ARBs, and potassium-sparing diuretics.
ð· None of the listed agents (citalopram, St. Johnâs Wort, famotidine) directly indicate hyperkalemia as the priority risk.
an adverse effect of famotidine
ð·Famotidineâs common effects (e.g., headache, mild GI changes) do not create the high-risk emergency pattern seen with serotonergic overload.
ð·It does not explain the major safety concern in this medication combination.
an interaction between citalopram and famotidine
ð·This combination is not the classic high-risk interaction in depression management compared with serotonergic herb use.
ð·The major danger in this case is adding St. Johnâs Wort to an SSRI.
a family history of type 2 diabetes mellitus
ð·Family history increases long-term cardiometabolic risk, but it does not identify the most urgent medication-related complication.
ð· The scenario highlights an immediate interaction risk rather than chronic metabolic risk.
an adverse effect of citalopram
ð·While SSRIs can cause GI effects and insomnia, the clientâs major risk comes from combining serotonergic agents.
ð· The herb-SSRI interaction is more dangerous than typical SSRI side effects.